Margaret McGlynn - Vertex Pharmaceuticals Independent Director

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

Earning Report: February 4, 2020  

  Director
Ms. Margaret G. McGlynn is Independent Director of Vertex Pharmaceuticals Incorporated. Ms. McGlynn retired from Merck Co. in 2009, where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products. During her 26 year career at Merck, she also held various leadership roles in the U.S. and globally in marketing, sales, managed care and business development. Following her retirement, Ms. McGlynn served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global notforprofit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015. Ms. McGlynn serves as a member of the Board of Directors for Air Products and Chemicals, Inc., a company specializing in gases and chemicals for industrial uses, and Amicus Therapeutics, Inc., a biopharmaceutical company. She is also a member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Age: 58  Director Since 2011  MBA    
617 341-6100  www.vrtx.com
McGlynn holds a B.S. in Pharmacy and an M.B.A. in Marketing from the State University of New York at Buffalo.

Margaret McGlynn Latest Insider Activity

Management Efficiency

The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Anthony ColesRegeneron Pharmaceuticals
2017
Larry CordellOrigin Agritech Limited
2012
Huda ZoghbiRegeneron Pharmaceuticals
2016
Herman MorrisPerrigo Company Plc
1999
Frank DAmelioZoetis
2016
Gary KunklePerrigo Company Plc
2009
Geoffery MerszeiOrigin Agritech Limited
2016
Prasad MenonDr Reddys Laboratories Ltd
2019
Paul BisaroZoetis
2015
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Michael JandernoaPerrigo Company Plc
2007
Michael BrownRegeneron Pharmaceuticals
1991
Ellen HoffingPerrigo Company Plc
2008
Hans HaslerDr Reddys Laboratories Ltd
2016
Theodore SamuelstoPerrigo Company Plc
2017
Louise ParentZoetis
2013
Min TangOrigin Agritech Limited
2009
Fei WangOrigin Agritech Limited
2019
Allan ObermanDr Reddys Laboratories Ltd
2019
J MoreauDr Reddys Laboratories Ltd
2007
Jacqualyn FousePerrigo Company Plc
2012

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 30 shares of
few hours ago
Traded for 80.1
Purchased over 300 shares of
few hours ago
Traded for 9.16
Purchased over 50 shares of
few hours ago
Traded for 58.39
Also please take a look at World Market Map. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.